ABT

Abbott Laboratories
D

ABT

Arincen83/100B
115.550
USD
6.14
(5.61%)
Post Trading·115.230USD-0.320(-0.28%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Abbott Laboratories net income 1985–2026

Abbott Laboratories earned 920.00M USD in Q3 FY2026, the three months to 30 September 2026, down 44.0% on the same quarter a year before. Abbott Laboratories's net income over the last twelve months was 4.70B USD, down 66.4% on the twelve months before. In fiscal year 2025 it earned 6.52B USD, down 51.3% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Net income

Net income · +4.0% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20264.70B-66.37%9.75%48.23B
FY202531 Dec 20256.52B-51.32%14.72%44.33B
FY202431 Dec 202413.40B+134.18%31.95%41.95B
FY202331 Dec 20235.72B-17.45%14.27%40.11B
FY202231 Dec 20226.93B-1.95%15.88%43.65B
FY202131 Dec 20217.07B+57.31%16.42%43.08B
FY202031 Dec 20204.50B+21.91%12.99%34.61B
FY201931 Dec 20193.69B+55.70%11.56%31.90B
FY201831 Dec 20182.37B+396.44%7.74%30.58B
FY201731 Dec 2017477.00M-65.93%1.74%27.39B
FY201631 Dec 20161.40B-68.35%6.71%20.85B
FY201531 Dec 20154.42B+93.65%21.68%20.41B
FY201431 Dec 20142.28B-11.34%11.28%20.25B
FY201331 Dec 20132.58B-56.80%11.79%21.85B
FY201231 Dec 20125.96B+26.12%14.95%39.87B
FY201131 Dec 20114.73B+2.20%12.17%38.85B
FY201031 Dec 20104.63B-19.49%13.15%35.17B
FY200931 Dec 20095.75B+17.73%18.68%30.77B
FY200831 Dec 20084.88B+35.34%16.53%29.53B
FY200731 Dec 20073.61B+110.07%13.92%25.91B
FY200631 Dec 20061.72B-49.09%7.64%22.48B
FY200531 Dec 20053.37B+4.21%15.10%22.34B
FY200431 Dec 20043.24B+17.53%16.44%19.68B
FY200331 Dec 20032.75B-1.45%13.99%19.68B
FY200231 Dec 20022.79B+80.19%15.80%17.68B
FY200131 Dec 20011.55B-44.35%9.52%16.29B
FY200031 Dec 20002.79B+13.91%20.27%13.75B
FY199931 Dec 19992.45B+4.77%18.56%13.18B
FY199831 Dec 19982.33B+12.28%18.71%12.48B
FY199731 Dec 19972.08B+10.47%17.50%11.88B
FY199631 Dec 19961.88B+11.45%17.09%11.01B
FY199531 Dec 19951.69B+11.34%16.87%10.01B
FY199431 Dec 19941.52B+8.40%16.56%9.16B
FY199331 Dec 19931.40B+12.91%16.64%8.41B
FY199231 Dec 19921.24B+13.80%15.78%7.85B
FY199131 Dec 19911.09B+12.74%15.83%6.88B
FY199031 Dec 1990965.80M+12.33%15.68%6.16B
FY198931 Dec 1989859.80M+14.34%15.98%5.38B
FY198831 Dec 1988752.00M+18.87%15.23%4.94B
FY198731 Dec 1987632.60M+17.04%14.42%4.39B
FY198631 Dec 1986540.50M+16.16%14.20%3.81B
FY198531 Dec 1985465.30M—13.85%3.36B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Abbott Laboratories's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.